The EMA has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.
The European Medicines Agency (EMA) has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.
The survey addresses how the agency communicates to the general public, and focuses on information made public mainly through the EMA website, including press releases and news announcements. EMA plans to distribute the results of the analysis.
“This will provide valuable feedback to help us to better plan and carry out our communication activities,” noted Monika Benstetter, Head of Media and Public Relations at EMA. “This is the second communications survey, the first having taken place in 2015, and it is anticipated that this exercise will be repeated every two years.”
The survey will be open until May 31, 2017, and Benstetter estimates that it should take you no longer than 10 minutes to complete. To access it, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.